Results 71 to 80 of about 30,645 (194)

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B [PDF]

open access: yesHepatology, 2002
During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) seroconversion to its antibody (anti-HBe) often coincides with normalization of liver biochemical test and clinical remission, but data regarding long-term outcome after spontaneous seroconversion are still scarce.
Yao-Shih, Hsu   +6 more
openaire   +2 more sources

Estimated probabilities for each drug to be ranked as HBeAg seroconversion after a 2-year treatment.

open access: yes, 2017
Estimated probabilities for each drug to be ranked as HBeAg seroconversion after a 2-year treatment.
Lin Cao (294505)   +3 more
core   +1 more source

Soluble immune markers in the different phases of chronic hepatitis B virus infection

open access: yesScientific Reports, 2019
Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by
Steffen B. Wiegand   +12 more
doaj   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

open access: yesHepatology Research, Volume 56, Issue 6, Page 903-913, June 2026.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa   +2 more
wiley   +1 more source

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection [PDF]

open access: yesEvolution, Medicine, and Public Health, 2013
HBeAg seroconversion is an important stage in the evolution of a chronic hepatitis B virus (HBV) infection that usually leads to control of viral replication and a reduced risk for liver cirrhosis and cancer. Since current therapies for the HBV-associated liver inflammation that is known as chronic hepatitis B (CHB).
Warner, Brook G.   +2 more
openaire   +2 more sources

Factors associated with HBeAg seroconversion plus HBV DNA <2000 IU/mL 12 months post-treatment in treatment experienced HBeAg-positive CHB patients.

open access: yes, 2015
Continuous variables: median (25th, 75th percentiles); categorical variables: numbers(percentages)IFN: interferon; ALT: alanine aminotransferase; ULN: upper limit of normal; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigenFactors ...
Jee-Fu Huang (292609)   +10 more
core   +1 more source

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

open access: yesJournal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo   +12 more
wiley   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance

open access: yesMedComm, Volume 7, Issue 4, April 2026.
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng   +16 more
wiley   +1 more source

The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion

open access: yes, 2009
OBJECTIVES: The aim of this study was to compare the virological and biochemical relapse rates in Asian chronic hepatitis B patients with lamivudine-induced hepatitis B e antigen (HBeAg) seroconversion, between those who stopped therapy after HBeAg ...
Yuen, J   +6 more
core   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy